Dempsey PC, Larsen RN, Sethi P et al (2016;dc152336) Benefits for type 2 diabetes of interrupting prolonged sitting with brief bouts of light walking or simple resistance activities
Safety outcomes showed no significant difference between SGLT2i and placebo in nasopharyngitis, diarrhea, or hypoglycemia, albeit with a borderline increased risk of urinary tract infections
FDA status - what you need to know: These are compounded medications, not FDA-approved finished drug products
Smith, Carolyn A
It helps reduce visceral fat, improves insulin sensitivity, and directly modulates immune cell function, fostering an anti-inflammatory environment
Across multiple STEP trials, the enrollment criteria required a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity (excluding type 2 diabetes, which was studied separately)